MarketCapExport financials
Omnicell (OMCL)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
Omnicell Income Statement 2025-2008 | OMCL
Brief overview of financial results at Omnicell
This overview is based on financial performance over the past five years. The revenue attributed to Omnicell moved from 892 million dollars to 1.2 billion dollars between the two endpoints. The five-year change reached +32.8%, while CAGR stood at 5.8%. This represents moderate business growth.
At the gross-profit level, the result moved from 413 million dollars to 503 million dollars, a change of +21.8%. Costs absorbed a larger share of revenue over the period. Gross margin moved from 46.3% to 42.5%. The margin decline reflects a less favorable sales-and-cost structure.
EBITDA changed from $96.6 million to $84 million (−13.1%). EBITDA underperformed the top-line trend. EBITDA margin was 10.8% at the start and 7.1% at the end. Operating return per unit of revenue declined.
Over the period, net income shifted from $32.2 million to $2.1 million (−93.6%). Profit pressure may reflect higher operating, financing, or tax costs.
Market capitalization changed from $5 billion to $1.4 billion (−72.3%). Market expectations deteriorated over the period.
Overall conclusion
The indicators point to a weaker financial profile. The positive side is supported by a larger revenue base. The overall view is constrained by pressure on operating profitability, a weaker final result and weaker gross profitability. The next reporting periods will show whether revenue, margins, and final profitability can strengthen.
Annual Income Statement Omnicell
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Market Cap |
1.39 B | 1.78 B | 1.19 B | 2.53 B | 6.53 B | 5.02 B | 3.49 B | 2.47 B | 1.85 B | 1.28 B | 1 B | 1.13 B | 895 M | 523 M | 499 M | 414 M | 309 M | - |
Shares |
46 M | 46 M | 45.2 M | 44.4 M | 43.5 M | 42.6 M | 41.5 M | 39.2 M | 37.5 M | 36.2 M | 35.9 M | 35.6 M | 34.7 M | 33.3 M | 33.1 M | 32.7 M | 31.7 M | - |
Historical Prices |
30.2 | 38.6 | 26.3 | 56.9 | 150 | 118 | 81.3 | 65.1 | 49 | 35.9 | 28 | 31.8 | 25.8 | 15.8 | 15.5 | 12.7 | 9.74 | 13.1 |
Net Income |
2.05 M | 12.5 M | -20.4 M | 5.65 M | 77.8 M | 32.2 M | 61.3 M | 37.7 M | 20.6 M | 603 K | 30.8 M | 30.5 M | 24 M | 16.2 M | 10.4 M | 4.89 M | 444 K | - |
Revenue |
1.18 B | 1.11 B | 1.15 B | 1.3 B | 1.13 B | 892 M | 897 M | 787 M | 716 M | 693 M | 485 M | 441 M | 381 M | 314 M | 246 M | 222 M | 213 M | - |
Cost of Revenue |
681 M | 641 M | 650 M | 707 M | 577 M | 479 M | 460 M | 415 M | 394 M | 379 M | 237 M | 207 M | 177 M | 143 M | 110 M | 104 M | 108 M | - |
Gross Profit |
503 M | 471 M | 497 M | 589 M | 555 M | 413 M | 437 M | 372 M | 322 M | 314 M | 248 M | 234 M | 203 M | 171 M | 136 M | 118 M | 105 M | - |
Operating Income |
5.16 M | 337 K | -34.9 M | -2.32 M | 89.5 M | 35.5 M | 78.4 M | 44.4 M | 11.1 M | 21.4 M | 48.6 M | 49.6 M | 35.3 M | 27.1 M | 16.2 M | 9.53 M | 669 K | - |
Interest Expense |
- | - | - | - | - | - | - | - | - | - | - | - | -270 K | -51 K | 62 K | 4 K | 15 K | - |
EBITDA |
84 M | 82.6 M | 52.5 M | 84.6 M | 162 M | 96.6 M | 142 M | 95.7 M | 57.3 M | 64.8 M | 70.8 M | 69.9 M | 53.7 M | 40.5 M | 24.2 M | 18.1 M | 10.1 M | - |
Operating Expenses |
498 M | 471 M | 532 M | 591 M | 465 M | 378 M | 359 M | 328 M | 316 M | 307 M | 203 M | 184 M | 168 M | 143 M | 120 M | 108 M | 105 M | - |
General and Administrative Expenses |
410 M | 380 M | 435 M | 486 M | 389 M | 308 M | 290 M | 263 M | 250 M | 250 M | 168 M | 156 M | 139 M | 120 M | 97.5 M | 86.2 M | 85.7 M | - |
Annual performance
Select metrics to display
All numbers in USD currency
Quarterly Income Statement Omnicell
| 2026-Q2 | 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Shares |
45.6 M | 45.3 M | 45.5 M | 46.8 M | 46.6 M | 46.4 M | 46.2 M | 46 M | 45.7 M | 45.5 M | 45.3 M | 45.1 M | 44.9 M | 44.7 M | 44.4 M | 44.2 M | 44.2 M | 44.2 M | 43.6 M | 43.3 M | 43 M | 42.8 M | 42.8 M | 42.7 M | 42.4 M | 42.1 M | 41.8 M | 41.4 M | 40.7 M | 40.3 M | 39.4 M | 39 M | 38.6 M | 38.4 M | 37.7 M | 37.2 M | 36.8 M | 36.6 M | 36.3 M | 36 M | 35.7 M | 53.9 M | 35.8 M | 36.1 M | 36 M | 35.8 M | 36 M | 35.7 M | 35.2 M | 35 M | 35.1 M | 34.4 M | 33.9 M | 33.5 M | 33.2 M | 33.4 M | 33.4 M | 33.2 M | 33.2 M | 33 M | 33.2 M |
Net Income |
24.3 M | 11.4 M | 5.46 M | 5.64 M | -7.02 M | - | 8.63 M | 3.74 M | -15.7 M | - | 5.55 M | 3.45 M | -15 M | - | 16.8 M | 9.07 M | 8.21 M | - | 29.3 M | 20.4 M | 14.1 M | - | 8.8 M | -4.3 M | 11.3 M | - | 20 M | 16 M | 3.28 M | - | 13.6 M | 6.59 M | 2.72 M | - | 7.75 M | 1.88 M | -10.3 M | - | 1.98 M | -1.16 M | -378 K | - | 8.04 M | 8.75 M | 6.32 M | - | 7.3 M | 7.79 M | 6.19 M | - | 7.76 M | 6.02 M | 3.38 M | - | 6.92 M | 1.38 M | 2.35 M | - | 2.99 M | 2.59 M | 670 K |
Revenue |
312 M | 310 M | 311 M | 291 M | 270 M | - | 282 M | 277 M | 246 M | - | 299 M | 299 M | 291 M | - | 348 M | 331 M | 319 M | - | 296 M | 273 M | 252 M | - | 214 M | 200 M | 230 M | - | 229 M | 217 M | 203 M | - | 204 M | 189 M | 183 M | - | 187 M | 181 M | 149 M | - | 177 M | 173 M | 171 M | - | 125 M | 113 M | 116 M | - | 113 M | 105 M | 102 M | - | 94 M | 93.7 M | 87.1 M | - | 84.3 M | 75.4 M | 64.1 M | - | 64.4 M | 61 M | 57.2 M |
Cost of Revenue |
159 M | 170 M | 176 M | 163 M | 159 M | - | 160 M | 162 M | 154 M | - | 167 M | 165 M | 166 M | - | 189 M | 173 M | 169 M | - | 150 M | 136 M | 130 M | - | 117 M | 116 M | 120 M | - | 117 M | 113 M | 105 M | - | 105 M | 99.9 M | 100 M | - | 102 M | 103 M | 86.4 M | - | 95.2 M | 94.9 M | 91.1 M | - | 61.5 M | 55.3 M | 54.5 M | - | 53 M | 49 M | 47.3 M | - | 42 M | 44.3 M | 41.7 M | - | 38.2 M | 36 M | 28.4 M | - | 30 M | 27.2 M | 25.5 M |
Gross Profit |
153 M | 140 M | 135 M | 128 M | 111 M | - | 122 M | 114 M | 92.6 M | - | 132 M | 134 M | 125 M | - | 159 M | 158 M | 150 M | - | 147 M | 136 M | 122 M | - | 96.8 M | 83.2 M | 110 M | - | 112 M | 104 M | 97.1 M | - | 98.9 M | 88.8 M | 82.5 M | - | 84.8 M | 78.1 M | 62.2 M | - | 81.5 M | 78 M | 79.9 M | - | 63.7 M | 57.5 M | 61.7 M | - | 59.5 M | 56 M | 54.5 M | - | 52 M | 49.4 M | 45.4 M | - | 46.1 M | 39.4 M | 35.7 M | - | 34.4 M | 33.8 M | 31.6 M |
Operating Income |
32.4 M | 16.9 M | 8.24 M | 8.12 M | -11.6 M | - | 6.56 M | 3.22 M | -21.8 M | - | 3.71 M | 7.75 M | -23 M | - | 18.5 M | 12.5 M | 5.08 M | - | 29.4 M | 28.9 M | 19.6 M | - | 10.2 M | -6.99 M | 12.2 M | - | 24.6 M | 18.8 M | 12.8 M | - | 17.5 M | 7.33 M | 633 K | - | 12.2 M | -701 K | -16.6 M | - | 4.93 M | -118 K | 1.85 M | - | 13.9 M | 12.4 M | 10.4 M | - | 13.6 M | 12.6 M | 9.95 M | - | 10.7 M | 9.36 M | 4.17 M | - | 11.2 M | 2.43 M | 3.64 M | - | 4.79 M | 4.23 M | 1.03 M |
Interest Expense |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -706 K | -40 K | -256 K | - | 25 K | 63 K | -223 K | - | 34 K | -73 K | 96 K | - | -191 K | 71 K | 54 K |
EBITDA |
51.2 M | 35.4 M | 27.6 M | 27.7 M | 8.38 M | - | 26.8 M | 24 M | -594 K | - | 10.4 M | 14.3 M | -989 K | - | 24.3 M | 18.1 M | 26.2 M | - | 82.5 M | 63.9 M | 37.2 M | - | 54.1 M | 21.8 M | 26.2 M | - | 64.2 M | 44.6 M | 25.4 M | - | 55 M | 32.2 M | 12.9 M | - | 50.7 M | 25.2 M | -4.1 M | - | 48.8 M | 29.1 M | 16.3 M | - | 32.3 M | 24.4 M | 16.1 M | - | 18.9 M | 17.3 M | 14.6 M | - | 15.2 M | 14.1 M | 8.64 M | - | 15.1 M | 5.43 M | 5.97 M | - | 10.6 M | 8.02 M | 2.88 M |
Operating Expenses |
120 M | 124 M | 126 M | 120 M | 123 M | - | 116 M | 111 M | 114 M | - | 128 M | 127 M | 148 M | - | 141 M | 146 M | 145 M | - | 117 M | 107 M | 103 M | - | 86.6 M | 90.2 M | 97.5 M | - | 87.5 M | 85.3 M | 84.4 M | - | 81.4 M | 81.4 M | 81.8 M | - | 72.6 M | 78.8 M | 78.7 M | - | 76.6 M | 78.1 M | 78.1 M | - | 49.8 M | 45 M | 51.3 M | - | 45.9 M | 43.5 M | 44.5 M | - | 41.3 M | 40 M | 41.2 M | - | 34.9 M | 36.9 M | 32.1 M | - | 29.7 M | 29.6 M | 30.6 M |
General and Administrative Expenses |
100 M | 102 M | 102 M | 98 M | 102 M | - | 94.5 M | 90 M | 92.4 M | - | 104 M | 104 M | 125 M | - | 115 M | 119 M | 120 M | - | 97.9 M | 89.2 M | 86.6 M | - | 71.4 M | 69.4 M | 78.8 M | - | 70.9 M | 68.4 M | 68.3 M | - | 65.6 M | 65.9 M | 65.3 M | - | 56.2 M | 61.9 M | 61.9 M | - | 61.3 M | 64.3 M | 64.3 M | - | 40.7 M | 39.7 M | 43.3 M | - | 38.9 M | 37 M | 38.4 M | - | 34.8 M | 32.9 M | 33.2 M | - | 29.3 M | 31.4 M | 25.6 M | - | 23.6 M | 24.3 M | 25.8 M |
Quarterly performance
Select metrics to display
All numbers in USD currency
The income statement is one of the three key financial reports of a company Omnicell (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:
- How much revenue the company earned
- How much it spent on production, personnel, marketing, taxes, etc.
- What profit remained in the end
Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.
Features- The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
- Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
- A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.
Reports on the profits and losses of other stocks in the Health information services industry
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
 |
Health Catalyst
HCAT
|
$ 1.74 | -0.57 % | $ 122 M |  USA |
 |
So-Young International
SY
|
$ 2.19 | -3.1 % | $ 171 M |  China |
 |
Teladoc Health
TDOC
|
$ 6.3 | 1.45 % | $ 1.11 B | USA |
 |
HealthEquity
HQY
|
$ 97.88 | 1.33 % | $ 8.43 B | USA |
 |
Veeva Systems
VEEV
|
$ 320.55 | 0.59 % | $ 52.5 B | USA |
 |
Schrödinger
SDGR
|
$ 23.9 | 2.14 % | $ 1.76 B | USA |
 |
Zhongchao
ZCMD
|
$ 1.34 | -4.96 % | $ 4.58 M | China |
 |
Castlight Health, Inc.
CSLT
|
- | -7.28 % | $ 227 M | USA |
 |
HMS Holdings Corp.
HMSY
|
- | - | $ 3.29 B | USA |
 |
Inovalon Holdings, Inc.
INOV
|
- | - | $ 6.37 B | USA |
 |
HealthStream
HSTM
|
$ 33.51 | -0.77 % | $ 1.01 B | USA |
 |
Progyny
PGNY
|
$ 28.44 | -0.49 % | $ 2.42 B | USA |
 |
10x Genomics
TXG
|
$ 75.59 | 5.78 % | $ 9.43 B | USA |
 |
Computer Programs and Systems
CPSI
|
- | 4.4 % | $ 133 M | USA |
 |
Akerna Corp.
KERN
|
- | - | $ 161 M | USA |
 |
MTBC
MTBC
|
- | -0.58 % | $ 51.7 M | USA |
 |
Premier
PINC
|
- | - | $ 2.33 B | USA |
 |
Streamline Health Solutions
STRM
|
- | - | $ 21.4 M | USA |
 |
SCWorx Corp.
WORX
|
- | - | $ 7.71 M | USA |
 |
American Well Corporation
AMWL
|
$ 13.97 | 5.91 % | $ 224 M | USA |
 |
Evolent Health
EVH
|
$ 4.83 | -0.82 % | $ 552 M | USA |
 |
NextGen Healthcare
NXGN
|
- | - | $ 1.6 B | USA |
 |
Covetrus
CVET
|
- | - | $ 2.94 B | USA |
 |
1Life Healthcare
ONEM
|
- | - | $ 3.37 B | USA |
 |
R1 RCM
RCM
|
- | - | $ 3.81 B | USA |
 |
Change Healthcare
CHNG
|
- | - | $ 9.03 B | USA |
 |
Signify Health
SGFY
|
- | -0.02 % | $ 7.21 B | USA |
 |
Tabula Rasa HealthCare
TRHC
|
- | - | $ 255 M | USA |
 |
Cerner Corporation
CERN
|
- | - | $ 27.9 B | USA |
 |
iCAD
ICAD
|
- | - | $ 102 M | USA |
 |
Accolade
ACCD
|
- | 0.29 % | $ 206 M | USA |
 |
Allscripts Healthcare Solutions
MDRX
|
- | -10.39 % | $ 886 M | USA |
 |
NantHealth
NH
|
- | -46.64 % | $ 10.4 M | USA |
 |
OptimizeRx Corporation
OPRX
|
$ 9.37 | 4.93 % | $ 174 M | USA |
 |
Phreesia
PHR
|
$ 12.26 | 1.78 % | $ 732 M | USA |
 |
GoodRx Holdings
GDRX
|
$ 3.57 | 1.42 % | $ 1.27 B | USA |